Drug Profile
TRX 518
Alternative Names: Anti-GITR monoclonal antibody - Leap Therapeutics; Anti-GITR-mAB; Anti-human-GITR-monoclonal-antibody; Anti-TNFRSF18 monoclonal antibody; TRX518Latest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator Tolerx
- Developer GITR Inc; Leap Therapeutics; Merck KGaA; Pfizer
- Class Antineoplastics; Antivirals; Monoclonal antibodies
- Mechanism of Action T lymphocyte stimulants; TNFRSF18 protein stimulants; Tumour necrosis factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma; Ovarian cancer; Prostate cancer; Solid tumours; Triple negative breast cancer; Viral infections
Most Recent Events
- 31 Dec 2021 Leap Therapeutics has patent protection for TRX 518 in USA, Australia, Canada, Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Sweden, Switzerland, and the United Kingdom), Hong Kong, India and Japan
- 31 Dec 2021 Leap Therapeutics has patents pending for TRX 518
- 28 Mar 2021 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)